Etherington Robert Dee Buys 65,000 Shares of CLNN
CLNN's CEO made a notable insider purchase, acquiring 65,000 shares.
Key Points
- On June 11, 2026, Etherington Robert Dee, President & CEO of CLNN, bought 65,000 shares at no cost.
- CLNN shares traded at around $5.78, with several institutional investors adjusting their positions.
- Analysts from HC Wainwright & Co. and D. Boral Capital maintain a 'buy' rating with high price targets.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 11, 2026, Etherington Robert Dee, the President and CEO of CLNN, made a significant insider purchase by acquiring 65,000 shares of the company. This transaction was recorded at no purchase price.
Other Institutional Activity in CLNN
Several institutional investors have also been active with CLNN shares. Boxer Capital Management, LLC increased its holdings by 277,778 shares, bringing its total to 477,515 shares valued at approximately $2.35 million. Meanwhile, Symbiosis Capital Partners, LLC reduced its position by 339,401 shares, now holding 431,094 shares worth about $2.12 million. Vanguard Capital Management LLC added 308,230 shares, ending with the same number of shares valued at $1.52 million. Scoggin Management LP and Ensign Peak Advisors, Inc also increased their stakes, with changes of 25,000 and 143,511 shares respectively.
Clene Inc. Stock Up 36.6%
Shares of CLNN are trading around $5.78. The stock has seen various institutional movements, reflecting its dynamic market presence. Despite the lack of detailed financial metrics, the recent insider activity suggests ongoing interest and confidence in the company's potential.
Insider Buying and Selling at Clene Inc.
Alongside Etherington's purchase, other executives have also been acquiring shares. On June 11, 2026, Morgan Brown, the Chief Financial Officer, bought 15,000 shares, while Mark Mortenson, the Chief Science Officer, purchased 45,000 shares. These transactions were also recorded at no purchase price, indicating a coordinated acquisition effort by the company's leadership.
Analysts Set New Price Targets
Analysts remain optimistic about CLNN's prospects. On May 4, 2026, HC Wainwright & Co. reiterated a 'buy' rating with a price target of $31. D. Boral Capital also maintained a 'buy' rating with a $23 price target on the same day. Canaccord Genuity had previously set a target of $48, reinforcing the positive sentiment among analysts.
About CLNN
CLNN is a company operating in the healthcare sector, focusing on innovative treatments and therapies. The company is led by CEO Etherington Robert Dee and is committed to advancing its research and development efforts.
Bottom Line
The insider purchases by CLNN's top executives, including CEO Etherington Robert Dee, highlight their confidence in the company's future. While 13F filings provide a historical snapshot and don't necessarily reflect current positions, the recent insider activity and analyst ratings suggest a positive outlook. Investors often track such moves for insights into the company's potential trajectory.
Get Clene Inc. alerts
New 13F filings, insider trades, and analyst moves on $CLNN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.